18F-FLT MicroPET评估顺铂对A549肺癌早期疗效反应的研究

18F-FLT MicroPET Imaging of Early Anti-tumor Response to Cisplatin on Lung Cancer

  • 摘要: 目前实体瘤疗效评价标准存在诸多不足,为了对抗肿瘤药的早期药效进行更精准的评价,给肺癌A549模型鼠以灌胃方式灌注顺铂进行治疗,并于给药前后分别进行18F-FLT MicroPET显像,根据瘤组织的放射性摄取值变化评价顺铂对肺癌A549模型鼠的早期疗效,同时采用传统抗肿瘤药药效评价方法作对比,结合病理切片进一步验证实验结果。结果显示,给药第2天,MicroPET显像可见治疗组肿瘤的放射性摄取由(4.91±0.71)%ID·g-1降至(3.87±0.61)%ID·g-1,降幅达21.28%;而治疗组和空白组的肿瘤体积在给药后9 d才出现显著性差异(P<0.01)。以上结果表明,18F-FLT MicroPET显像较传统的肿瘤体积测量能更早、更精准地评价顺铂的抗肿瘤药效。

     

    Abstract: In order to investigate the feasibility of 18F-FLT MicroPET in the early efficacy of the antineoplastic drug. Twelve A549 lung carcinoma-loaded mice were randomly divided into 2 groups(control and treatment group, n=6 in each group). Cisplatin (DDP, 25 mg/kg) and saline were injected intragastricaly everyday to the treatment and control group, respectively. Tumor volume and weight were detected everyday and 18F-FLT MicroPET scans were performed at 0, 2, 5, 9, 14 d. The MicroPET results showed that after the second administration, the tumor uptake of treatment group decreased 21.28%, from (4.91±0.71)%ID/g to (3.87±0.61)%ID/g, while tumor volume was significantly decreased until 9 d (P<0.01). Compared with traditional method, MicroPET can detect much earlier and more accurate efficacy of antitumor agents.

     

/

返回文章
返回